Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

3.370 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	14,867
Open	3.370
Bid (Size)	3.340 (400)
Ask (Size)	3.370 (200)
Prev. Close	3.370
Today's Range	3.370 - 3.370
52wk Range	2.830 - 15.74
Shares Outstanding	61,758,994
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud

June 04, 2026

From Levi & Korsinsky

Via Business Wire

Keep an eye on the top gainers and losers in Tuesday's session. ↗

June 02, 2026

Via Chartmill

Performance

YTD	-69.1%	-69.1%
1 Month	-52.0%	-52.0%
3 Month	-58.7%	-58.7%
6 Month	-61.5%	-61.5%
1 Year	-52.1%	-52.1%

More News

These stocks are moving in today's session ↗

June 02, 2026

Via Chartmill

Tuesday's session: gap up and gap down stocks ↗

June 02, 2026

Via Chartmill

Fulcrum Therapeutics (NASDAQ:FULC) Beats Q1 Estimates as Pociredir Data Fuels Optimism ↗

April 27, 2026

Via Chartmill

Fulcrum Therapeutics (NASDAQ:FULC) Q4 2025 Earnings: Pociredir Data Steals Spotlight Amid In-Line Financials ↗

February 24, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

June 02, 2026

Via Chartmill

Which stocks are moving after the closing bell on Monday? ↗

June 01, 2026

Via Chartmill

Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

June 01, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 08, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum (FULC) Q1 2026 Earnings Transcript ↗

April 27, 2026

Via The Motley Fool

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

April 27, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

April 27, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET

April 20, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics

March 26, 2026

Via MarketMinute

Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data

March 26, 2026

Via MarketMinute

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease

March 19, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

March 03, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

February 24, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

February 24, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

February 17, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 09, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Fulcrum Therapeutics, Inc. - Common Stock publicly traded?

Yes, Fulcrum Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Fulcrum Therapeutics, Inc. - Common Stock trade on?

Fulcrum Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock?

The ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock is FULC on the Nasdaq Stock Market

What is the current price of Fulcrum Therapeutics, Inc. - Common Stock?

The current price of Fulcrum Therapeutics, Inc. - Common Stock is 3.370

When was Fulcrum Therapeutics, Inc. - Common Stock last traded?

The last trade of Fulcrum Therapeutics, Inc. - Common Stock was at 06/04/26 04:00 PM ET

What is the market capitalization of Fulcrum Therapeutics, Inc. - Common Stock?

The market capitalization of Fulcrum Therapeutics, Inc. - Common Stock is 208.13M

How many shares of Fulcrum Therapeutics, Inc. - Common Stock are outstanding?

Fulcrum Therapeutics, Inc. - Common Stock has 208M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.